Introduction
============

Distal myopathies form a heterogeneous group of disorders characterized by progressive muscular atrophy and weakness, beginning in distal and proceeding to proximal limb muscles. Age at onset, inheritance pattern and clinical as well as histopathological features have been used to distinguish different forms with linkage to different genetic loci or genes. The autosomal dominant inherited distal myopathies are: (i) Welander myopathy, a late adult onset myopathy (MIM 604454) with clinical onset in the hands and linkage to chromosome 2p13 ([@B2]); (ii) Udd distal myopathy (MIM 600334), which starts with weakness in the anterior compartment of the lower leg and is caused by mutations in the *Titin (TTN)* (MIM 188840**)** gene ([@B21]; [@B18]); (iii) the late adult onset zaspopathy (Markesbery--Griggs) caused by mutations in the LIM domain binding 3 *ZASP* (MIM 605906) gene ([@B16]), which begins after 40 years of age with ankle dorsiflexion weakness, progressing to finger and wrist extensors; (iv) a new adult onset form caused by mutations in Matrin3 (*MATR3*) has recently been described ([@B37]). A distinguishing feature of *MATR3* mutations is vocal cord paralysis and pharnygeal weakness but these were not present in all affected family members; (v) early adult/infantile onset Laing myopathy (MIM 160500), which starts in the anterior compartment of the lower leg, shows autosomal dominant inheritance and is caused by mutations in the tail of myosin heavy chain 7 (*MYH7*) (MIM 160760) gene located at chromosome 14q11 ([@B28]; [@B48]; [@B33]); and (vi) Mahjneh *et al*. (2003) reported a distal myopathy from Finland (MIM 610099) with adult onset and rimmed vacuoles, which showed significant linkage to two separate loci, 8p22-q11 and 12q13-q22 (Mahjneh *et al*, 2003; [@B20]). The autosomal recessively inherited types include: (i) early onset Nonaka myopathy (MIM 605820), which starts with onset in the distal legs. Mutations in the *UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase* (*GNE*) (MIM 603824) gene on chromosome 9p12-p13 are associated with the hereditary inclusion body myopathy ([@B14]) (MIM 600737) and are also described in Nonaka myopathy ([@B25]); (ii) early adult onset Miyoshi myopathy (MIM 254130), which affects calf muscles, is caused by mutations in the *Dysferlin* gene (MIM 603009) on chromosome 2p13 ([@B31]; [@B4]) and is allelic to limb girdle muscular dystrophy 2B (MIM 253601); and (iii) homozygous missense mutations in the *Nebulin (NEB)* gene which cause childhood to early adulthood onset distal myopathy with ankle dorsiflexor, finger extensor and neck flexor weakness (MIM 161650). The progression is mild, and the patients remain ambulant ([@B49]).

Furthermore, families with uncomplicated distal myopathy but without a known genetic cause have been reported ([@B45], [@B46]), and several reports describe families with distal myopathy associated with features such as joint contractures and kyphoscoliosis ([@B5]), external ophthalmoplegia, weakness of pharynx muscles and respiratory failure (MIM 607569) ([@B47]). Interestingly, a family with adult onset dominant distal vacuolar myopathy with additional features including dysphonia, dysphagia, pes cavus and areflexia was mapped to chromosome 19p13.3 ([@B38]). This locus has been further confirmed in a family with autosomal dominant distal myopathy, but the additional clinical features were less striking (Di [@B11]).

The myofibrillar myopathies are an important differential diagnosis, e.g. the above mentioned zaspopathy, and other gene mutations such as in the *Desmin* and *Myotilin* genes, which mainly present as a distal myopathy ([@B45], [@B46]).

Here, we describe a novel form of early onset distal myopathy with autosomal dominant inheritance in a large German family. Affected family members developed mild sensory disturbances in stocking-glove distribution later in life, a distinguishing feature for distal myopathy. We mapped the disease to a new locus on chromosome 9p21.2-p22.3. Screening of candidate genes resulted in the identification of a heterozygous missense mutation c.796 T\>C (NM_018847.1) leading to a p.L95F mutation in the *kelch-like homologue-9 (KLHL9)* gene, which segregated with the disease phenotype. Molecular modelling and immunoprecipitation studies showed that the mutation reduces interaction with Cullin 3 (Cul3) in the KLHL9--Cul3--Roc1 E3 ubiquitin ligase complex.

Materials and methods
=====================

Patients and clinical evaluation
--------------------------------

We studied four generations of a German family with distal myopathy ([Fig. 1](#F1){ref-type="fig"}). Ten affected members, three unaffected members and two with unclear status from three generations were examined physically, while the remaining family members were contacted by phone. The muscle biopsies were obtained from the index patient (950307) at the age of 17 years from the gastrocnemius muscle during an Achilles tendon release surgery, and at the age of 32 years from the vastus lateralis muscle via Bergström needle. The biopsy specimens were processed in the neuropathology laboratory using standard protocols for haematoxylin-eosin, nicotinamide adenine dinucleotide and trichrome staining. Immunhistochemistry of muscle sections were performed as described elsewhere ([@B22]). The study was approved by the Ethical Review Board of the University of Essen. Informed consent was obtained from all family members. Figure 1Pedigree. Circles denote females, squares denote males, slashed symbols indicate death, filled symbols indicate the diagnosis of distal myopathy. The index patient is indicated with a red arrow. The symbols filled with grey colour and a question mark indicate that the affection status of these family members could not be identified because of either death or that, at the age of examination, they were considerably younger than the age of onset. All family members with a six-digit identification number were genotyped. This shows the pedigree that was used for the exclusion of distal myopathy loci and the genome scan.

Analysis of linkage with known distal myopathy loci
---------------------------------------------------

DNA was isolated from peripheral lymphocytes using standard protocols. For exclusion of previously described loci for distal myopathy we used the following polymorphic microsatellite markers: locus 2p12-p14 (Miyoshi myopathy and Welander myopathy): D2S303, D2S292, D2S291, D2S169 and D2S329; locus 2q31-q33 (Udd myopathy): D2S138, D2S148, D2S300, D2S385, D2S324, D2S2310, D2S1391, D2S152, D2S389 and D2S315; Locus 9p12-p13 (Nonaka myopathy): D9S43, D9S248, D9S165 and D9S50; and locus 14q11 (Laing myopathy): D14S72, D14S283, D14S50, MYH7, D14S64, D14S54 and D14S49. Polymerase chain reactions (PCRs) were performed with fluorescent end-labelled microsatellite markers and semi-automated genotyping was performed on an ABI 377 (Applied Biosystems) Sequencer using the Genotyper V 3.7 (Applied Biosystems) software.

Genome scan
-----------

The genome scan was performed using the core pedigree shown in [Fig. 1](#F1){ref-type="fig"}. We performed a genome-wide scan with 439 microsatellite markers that had an average marker density of 7.76 ± 3.80 cm (Marshfield) ([@B23]). PCRs of fluorescent labelled microsatellite markers were performed as described elsewhere ([@B44]). The genotyping was done by a MegaBACE-1000 (Amersham) analysis System using the Genetic Profiler Software 1.5 (Amersham). PedCheck ([@B34]) was used for detection of Mendelian errors. The correct relationships in families were confirmed by the program Graphical Relationship Representation ([@B1]). Two-point linkage analyses were performed using the software FASTLINK v4.1 ([@B9]), multipoint linkage analyses using Genehunter v2.1 ([@B26]) and Simwalk v2.86 ([@B40]). We assumed an autosomal-dominant model with 100% penetrance, equally distributed alleles and a disease allele frequency of 0.0001. Haplotype reconstruction was done by Simwalk2 v2.86 and Genehunter v2.1. The fine mapping was performed using the extended pedigree shown in [Fig. 3](#F3){ref-type="fig"}B. Subsequent fine mapping included markers D9S274, D9S156, D9S1778, D9S161 and D9S270.

Sequencing of candidate genes and mutational analysis of *KLHL9*
----------------------------------------------------------------

The following genes were chosen as candidate genes according to NCBI Human Genome draft number 35: *ADAMTSL* (a disintegrin and metalloproteinase with thrombospondin motif-like)*, KIAA1354 (KLHL9), FLJ39267, TEK* (endothelial tyrosine kinase) and *CCDC2* (coiled coil domain containing 2)*.* Based on the predicted and annotated sequences, primers pairs were designed using the Primer 3 program ([@B36]) (primer sequences used available on request). All coding exons with exon-intron boundaries were amplified from genomic DNA and both strands of the PCR products were sequenced using Big-Dye Terminator 1.1 (Applied Biosystems) on an ABI 3730xl sequencer (Applied Biosystems). We performed sequence comparisons using the DNASTAR package (Lasergene). Mutations indentified in the *KLHL9* gene were confirmed by restriction enzyme digestion with Hind III (Fermentas) with the following primer pair: primer A (forward) CCCTTGATAAGGAAACGAGC, primer B (reverse) TGTTAGCAATTCGTCCAACC, which yielded a 602 bp product. PCR fragments containing the wild-type sequence had two restriction sites resulting in three digestion fragments 106, 207 and 289 bp. The mutation *KLHL9* abolishes the last restriction site and results in four digestion fragments of 106, 207, 289 and 496 bp in the heterozygous patients.

Reverse transcriptase polymerase chain reactions
------------------------------------------------

The tissue expression patterns of KLHL9 (NM_018847) and β-actin (NM_001101) as a control (NM_001101) were examined by reverse transcriptase polymerase chain reaction (RT-PCR) using a human 24 tissue rapid-scan cDNA panel (HSCA101; OriGene) with the following PCR primers:

*KLHL9*---FOR 2146 5′-GACCCCAATTGCCGCCATGTTA-3′;

*KLHL9*---REV---2340 5′-CAGGCTCGAATGCCACCAAGTG-3′;

*β-actin*---FOR 736 5′-GGACTTCGAGCAAGAGATGG-3′;

*β-actin*---REV 969 5′-AGCACTGTGTTGGCGTACAG-3′.

Each 25 µl PCR reaction consisted of: 2.5 µl 10× PCR buffer, 1 pmol forward primer, 1 pmol reverse primer, 1.25 µl 1 mM deoxynucleoside triphosphates, 1.5 mM MgCl~2~ and five units of Taq polymerase (Invitrogen, USA). The PCR conditions followed the manufacturer's recommendations: one cycle at 94°C for 3 min; 35 cycles at 94°C for 30 s, 55°C for 30 s, 72°C for 2 min; one cycle at 72°C for 5 min; 4°C hold. RT-PCR primers were designed using Primer3 ([@B36]). The products were resolved by agarose gel electrophoresis, visualized on an ultraviolet transilluminator and the images captured using a charge-coupled device camera system (Fotodyne Inc., USA). The expression levels of KLHL9 and β-Actin in each tissue type were quantified with MultiGauge v. 2.3 (Fujifilm Medical Systems, USA) and the ratios of KLHL9:β-actin expression were calculated and normalized to the expression levels of KLHL9 and β-actin in muscle tissue, which was assigned a value of '1', as shown in [Supplementary Table 1](http://brain.oxfordjournals.org/cgi/content/full/awq108/DC1).

Molecular modelling
-------------------

The structural model of the bric-a-brac (BTB)--Cul3 complex was generated through superposition of the Skp1--Cul1 domain (Protein Data Bank id: 1ldj) ([@B52]) and the promyelocytic leukemia zinc finger protein BTB domain (Protein Data Bank id: 1buo) ([@B3]) crystal structures ([@B41]). Molecular modelling and illustrations were generated with PyMOL (DeLano Scientific) ([@B10]). The location of the KLHL9 p.L95F mutation within the complex was identified by a sequence alignment of the BTB domains from promyelocytic leukemia zinc finger protein and KLHL9.

Expression vectors
------------------

The expression vector for human influenza hemagglutinin (HA) Tag-cullin 3 (HA-Cul3) has previously been described ([@B51]). The cDNA for human *KLHL9* (KIAA1354) was obtained from the Kazusa DNA Research Institute (Chiba, Japan) and sequenced to confirm its identity. The p.L95F amino-acid substitution was introduced with overlapping primers via a PCR-based approach with Pfu Turbo polymerase (Stratagene). For cloning purposes, flanking *Bam*HI and *Xho*I restriction sites were introduced by PCR with Pfu Turbo polymerase (Stratagene). To express wild-type or L95F mutant KLHL9 as N-terminal FLAG epitope-tagged proteins in mammalian cells, the cDNAs encoding wild-type KLHL9 and mutant L95F KLHL9 were cloned in frame into the pCMV-Tag2A expression vector (Stratagene). The wild-type and mutant p.L95F KLHL9 cDNAs were cloned into the *Bam*HI and *Xho*I sites of pCMV-Tag2A (Stratagene). The integrity of the entire coding region of both wild-type and p.L95F KLHL9 were verified by sequence analysis.

Human embryonic kidney 293T cell culture and transfections
----------------------------------------------------------

Human embryonic kidney 293T cells (ATCC CRL-11268) were cultured in a humidified 37°C, 5% CO~2~ incubator on 0.1% gelatine-coated tissue culture dishes in high glucose (4.5 g/l) Dulbecco's modified Eagle's medium supplemented with 2 mM [l]{.smallcaps}-glutamine, 10% heat-inactivated foetal bovine serum, amphotericin and gentamycin. For transfections, 9 × 10^5^ human embryonic kidney 293 T cells were seeded onto 0.1% gelatine-coated 60 mm tissue culture dishes on the day prior to transfection. Each 60 mm dish of human embryonic kidney cells was re-fed with 2 ml of Dulbecco's modified Eagle's medium lacking any additives and transfected with 3 µg of total plasmid DNA comprised of 750 ng of wild-type or p.L95F KLHL9 and either 0, 83.3, 250, 750 or 2250 ng of HA-Cul3 and empty pcDNA3.1 (Invitrogen) vector up to 3 µg total with 8 µl PLUS reagent (Invitrogen) and 12 µl Lipofectamine (Invitrogen) in the 37°C, 5% CO~2~ incubator. After a 4 h incubation period, the cells were re-fed with complete Dulbecco's modified Eagle's medium and returned to the 37°C, 5% CO~2~ incubator. Expression of the HA-Cul3, wild-type and p.L95F FLAG-KLHL9 constructs was confirmed by immunoblot analysis.

Immunoprecipitations and immunoblots
------------------------------------

At 40 h post-transfection, the transfected cells were washed with cold 1× phosphate buffered saline (pH 7.4) and cell lysates were collected in erythrocyte lysis buffer (50 mM HEPES, pH7.4, 250 mM NaCl, 5 mM EDTA, 0.1% Triton X-100) supplemented with 1 mM dithiothreitol, 1 mM NaF, 0.4 mM NaVO~3~, 1 mM phenylmethanesulphonyl fluoride and Protease Inhibitor Cocktail (Sigma) and clarified by centrifugation at 14 000*g* for 10 min at 4°C. Total protein concentration was determined by Bradford assay (Bio-Rad). Equivalent amounts of total protein were pre-cleared with protein A agarose (Sigma) for 1 h on the rotator at 4°C and subjected to overnight anti-FLAG M2 (F3165; Sigma) immunoprecipitations at 4°C, on the rotator. The immunoprecipitates were collected with protein A agarose (Sigma), extensively washed with erythrocyte lysis buffer, resolved by sodium dodecyl sulphate polyacrylamide gel electrophoresis, transferred to nitrocellulose and subjected to rabbit anti-HA (Covance) immunoblot analysis using the SuperSignal West Dura Extended Duration Substrate system (Thermo Fisher Scientific) enhanced chemiluminescence system. Images were captured using a charge-coupled device camera system (Fujifilm Medical Systems) and the expression levels of wild-type FLAG-KLHL9, mutant FLAG-L95F-KLHL9 and HA-Cul3 were determined using MultiGauge v. 2.3 (Fujifilm Medical Systems). The results are shown in [Supplementary Table 2](http://brain.oxfordjournals.org/cgi/content/full/awq108/DC1).

Results
=======

Family and index patient
------------------------

The pedigree encompassed 33 family members from four generations and indicated a dominant inheritance ([Figs 1](#F1){ref-type="fig"} and [3](#F3){ref-type="fig"}B). The family originated from the north of Germany. In total, 15 family members underwent physical examination, 10 of whom were affected. Two unaffected children were younger than the mean age at onset at the time of investigation. Hence their affection status was defined as 'unknown' for linkage analysis.

First symptoms of weakness appeared between the ages of 8 and 16 years, resulting in difficulties in walking on heels, followed by selective weakness and slow wasting of ankle extensors leading to a high stepping gait. Progression of weakness was very slow. The proximal muscle groups were generally spared. Common features of the affected family members were ankle contractures, reduced sensation in stocking distribution in lower limbs and weakness in intrinsic hand muscles. The ankle joint contractures might be a secondary phenomenon to drop foot. Some affected family members also had sensory symptoms in the hands. Nerve conduction studies available in some patients did not confirm a definite peripheral neuropathy. The serum creatine kinase levels were elevated and ranged between 200 and 1400 U/L. A summary of the clinical findings in other affected family members is provided in [Table 1](#T1){ref-type="table"}. The index patient is the most severe case in this family; all other affected family members have milder difficulties. Table 1Clinical details of the affected individualsPatient IDAge at examination (years)Age of onset (years)Atrophy of anterior tibial musclesContractures of anklesReduced sensationWeakness of intrinsic hand musclesCK (U/l)Other features95020263?++Lower leg, hand+170Reduced motor nerve conduction velocity of peroneal nerve (39 m/s)95020667?++Lower and upper leg, hand+200Deep tendon reflexes in legs not preserved9503024016++Lower leg, hand−1109503043910++Lower leg+1909503063413−(+)Lower leg(+)260Reduced amplitude 5.7 mV and increased distal motor latency with 6.9 ms of peroneal nerve with 51 m/s9503082513++Lower leg, hand+140950307258++Lower leg, hand+700--1400Deep tendon reflexes in legs reduced, surgical lengthening of the right tendon Achilles at age 17 years Peripheral axonal neuropathy9504021816−(+)−−1709504051210+(+)−−230[^1]

The index patient (950307, [Figs 1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}) experienced first symptoms at the age of 12 years with foot drop, heel walk difficulties and unsteady gait due to atrophy of anterior tibial muscles. Clinical examination at the age of 16 years showed a 'naked tibia' with ankle contractures and distinct atrophy of ankle extensors. Mild intrinsic hand muscle atrophy with formation of a *tabatière* was noticed at the age of 16 years. At 17 years of age, surgical lengthening of the right Achilles tendon was performed. Figure 2Clinical information from index Patient 950307. (**A**) Index patient at the age of 16 years, clearly with atrophy of anterior tibial muscles. (**B**) Index patient at the age of 32 years with the sign of the 'naked tibia' due to distal atrophy. (**C**) Axial T~1~-weighted spin echo images (Magnetom Symphony, Siemens, FGR: 1.5 Tesla system, repetition time of 377 ms, echo time 20 ms, two acquisitions, 10 mm slice thickness, field of view of 300 × 300 mm) showing the muscle MRI of distal thigh (I) and proximal lower limb (II). In the lower thigh, striking changes are evident in the semimembranosus, biceps femoris and vastus intermedius muscles. Fatty atrophy in the lower leg was pronounced in the tibialis anterior, gastrocnemius and soleus muscles with relative preservation of tibialis posterior and peroneus longus muscles. (**D**) Trichrom stain of the muscle biopsy from the gastrocnemius muscle at the age of 15 years showing a myopathic pattern with variation fibre size, atrophic fibres, replacement by fat and connective tissue and internal nuclei. Furthermore some peripheral nerves are visualized, which show normal myelinization. (**E**) Haematoxylin-eosin stain of the vastus lateralis muscle at the age of 32 years confirming the myopathic features and (**F**) the nicotinamide adenine dinucleotide stain of the same biopsy showing a loss of fibre typing. All images were captured with 20× objective lens. Figure 3Whole genome scan and haplotypes of the disease locus at chromosome 9p21.2-p23.3. (**A**) Genome-wide two point LOD scores are shown, one bar for every genotyped marker. The red bars indicated a maximum LOD score at recombination fraction *θ* = 0. The blue bars show markers with a positive LOD score with *θ* \> 0, the black bars stand for markers with negative LOD scores. The numbers of the chromosomes are shown under the *x*-axis, the marker distances are drawn according to the DeCODE Map. (**B**) This figure shows the haplotypes of the fine mapping using the extended pedigree. Circles denote females, squares denote males, slashed symbols indicate death, and filled symbols indicate the diagnosis of distal myopathy. The symbols filled with grey colour and a question mark indicate that the affection status of these family members could not be identified because of either death or that at the age of examination, they were considerably younger than the age of onset. All family members with a six-digit identification number were genotyped. The haplotypes were reconstructed using the Simwalk2 program. Uninformative or non-reconstructable markers are indicated with a black bar. The order of the microsatellite makers are from p-telomer to centromer according to the DeCODE Map. The disease haplotype is marked with a black square. Note that all affected family members carry the red haplotype. The index case is indicated with a red arrow.

Follow-up of the index patient at the age of 32 years showed muscle wasting of the lower limb muscles in particular the tibialis anterior muscles. Dorsal flexion and inversion of the ankles were not possible; flexion and eversion were very weak. There was moderate weakness of limb girdle muscles, particularly of the hip extensors. Hopping on one leg was impossible. The patient was still ambulant, with the use of callipers. Strength of proximal muscle groups in the arms was normal. Impairment of sensation, in particular touch and vibration, in the lower legs (up to the knees) and in the hands was observed. There was a slight postural tremor, and the intrinsic hand muscles showed weakness and atrophy. The Achilles and patellar muscle stretch reflexes could not be elicited. Touch and vibration senses were reduced. Cranial nerve examination was normal. Echocardiography, electrocardiogram and lung function testing were normal.

Nerve conduction studies and electromyography
---------------------------------------------

[Table 2](#T2){ref-type="table"} summarizes the results of nerve conduction studies performed in two patients. Table 2Nerve conduction studies**Motor conduction studiesSensory conduction studiesAge (years)Distal latency (ms)Conduction velocity (m/s)Amplitude (mV)Age (years)Conduction velocity (m/s)Amplitude (µV)**Patient 950307 Median R144.841n. a.Sural L1438n.a. Normal values[^a^](#TF3){ref-type="table-fn"}*\[3.2±0.7\]\[49.6±3.4\]\[7.2±1.6\]*Normal values[^a^](#TF3){ref-type="table-fn"}*\[40.6±4.8\]\[18.7±4.4\]* Peroneal L145.8[^b^](#TF4){ref-type="table-fn"}44n. a.Sural L31606.9 Normal values[^a^](#TF3){ref-type="table-fn"}*\[3.2±0.7\]\[49.6±3.4\]\[7.2±1.6\]*Normal values[^c^](#TF5){ref-type="table-fn"}*\[47.0±4.6\] (35.8--62.0)\[17.2±10.1\] (1.7--67.3)* Peroneal L and R31n.o.n.o.n.o. Tibial L313.75511.8 Tibial R314.5559.7 Normal values[^b^](#TF4){ref-type="table-fn"}*\[4.5 ± 0.8\] (3.2--6.9)\[47.0 ± 5.4\] (32.7--61.0)\[11.0 ± 5.2\] (0.3--25.6)*Patient 950306 Peroneal L346.9[^b^](#TF4){ref-type="table-fn"}515.7Sural L345313.8435.6595.5435518.6 Normal values[^c^](#TF5){ref-type="table-fn"}*\[4.6 ± 0.7\] (3.5--6.4)\[48.6 ± 5.1\] (32.4--59.6)\[5.6 ± 2.6\] (0.1--12.3)*Normal values[^c^](#TF5){ref-type="table-fn"}*\[47.0 ± 4.6\] (35.8--62.0)\[17.2 ± 10.1\] (1.7--67.3)* Tibial L434.66035.1Median L436234.6 Normal values[^c^](#TF5){ref-type="table-fn"}*\[4.5 ± 0.8\] (3.2--6.9)\[47.0 ± 5.4\] (32.7--61.0)\[11.0 ± 5.2\] (0.3--25.6)*Normal values[^c^](#TF5){ref-type="table-fn"}*\[52.0 ± 5.3\] (35.4--65.0)\[32.9 ± 17.6\] (3.1--86.0)* Median L433.85218.4Ulnar L435347.6 Normal values[^c^](#TF5){ref-type="table-fn"}*\[3.6 ± 0.6\] (2.4--5.9)\[56.0 ± 3.9\] (43.8--63.5)\[9.1 ± 3.3\] (1.7--19.5)*Normal values[^c^](#TF5){ref-type="table-fn"}*\[52.4 ± 4.1\] (40.3--62.9)\[29.8 ± 17.6\] (4.4--90.7)*[^2][^3][^4][^5]

Few distal motor latencies were found to be increased. In one study, the amplitude of the sural sensory nerve action potential was reduced. All other nerve conduction velocities were within normal limits.

An electromyography of anterior tibial, gastrocnemius and interosseus I dorsalis muscles in Patient 950307, performed at 14 years of age, revealed signs compatible with active denervation with fibrillation potentials and positive waves, as well as chronic neurogenic alteration most pronounced in lower limbs. Motor unit potentials were strikingly polyphasic, and recruitment of motor unit potentials was mildly reduced in the interosseus I dorsalis muscle and markedly reduced in tibial and gastrocnemius muscles. These changes might be partly secondary to myopathy and do not prove a peripheral neuropathy.

Imaging (Patient 950307 at 32 years of age)
-------------------------------------------

The muscle MRI ([Fig. 2](#F2){ref-type="fig"}C) with T~1~ images of the lower limbs showed symmetric fatty atrophy of muscles. In the lower thigh, the most significant changes were seen in the semimembranosus muscle, in the biceps femoris muscle as well as in the vastus intermedius muscle, whereas the lateral and medial vastus muscles and parts of the adductor muscles gracilis and sartorius were preserved. Fatty atrophy of the lower leg was pronounced in the tibialis anterior, gastrocnemius and soleus muscles with relative preservation of the tibialis posterior and peroneus longus muscles ([Fig. 2](#F2){ref-type="fig"}C).

Muscle biopsy (Patient 950307)
------------------------------

A muscle biopsy of the gastrocnemius muscle, taken at age 17 years, showed an increased variation in fibre size with atrophy and hypertrophy, disseminated atrophic fibres, replacement of muscle by fat and connective tissue, and an increase of internalized nuclei. No autophagic vacuoles or inclusions were seen ([Fig. 2](#F2){ref-type="fig"}D). A sural nerve biopsy, taken at 16 years of age, did not show any signs of axonal or demyelinating neuropathy. A second muscle biopsy of the vastus lateralis muscle, at 32 years of age, showed myopathic changes with fibre angulation and size variation, internal nuclei and increased connective tissue ([Fig. 2](#F2){ref-type="fig"}E). The NADH staining showed loss of fibre typing and angulated fibres ([Fig. 2](#F2){ref-type="fig"}F). As the vastus lateralis is less affected then distal muscle groups, it may not show the full range of histopathological changes. Immunocytochemistry showed normal expression of the cell-surface proteins dystrophin, caveolin, laminin α2 and of the dystroclycan-sarcoglycan complex (data not shown).

Linkage analysis
----------------

Previously described loci for autosomal dominant distal myopathy on chromosomes 2p12-p14 (Miyoshi- and Welander-myopathy), 2q31-q33 (Udd-myopathy), 9p1-q1 (Nonaka-myopathy) and 14q11 (Laing-myopathy) were excluded by haplotype reconstruction and did not show evidence for linkage \[logarithm of the odds ratio (LOD) \< −2\]. Therefore, we performed a genome wide linkage scan and subsequently identified a single disease region with a maximum two-point parametric LOD = 3.69 (D9S1870) at θ = 0 ([Fig. 3](#F3){ref-type="fig"}A, [Table 3](#T3){ref-type="table"}). Further fine mapping with an extended pedigree, with additional 10 markers, confirmed the locus at 9p21.2-p22.3 with a multipoint LOD = 4.21 within the interval between D9S1870 and D9S161 ([Supplementary Fig. 1](http://brain.oxfordjournals.org/cgi/content/full/awq108/DC1)). Haplotype analysis revealed critical recombination events in the affected individuals 950 322 (proximal border) and 950304 (distal border), defined D9S274 and D9S270 as the outer border markers of the disease haplotype ([Fig. 3](#F3){ref-type="fig"}B) and comprised 22.59 cM according to the DeCODE Map. Table 3Two point LOD scores generated at various recombination fractions (θ = 0--0.4) for the marker in the region 9p22.3-p21.2**MarkercM**[^a^](#TF6){ref-type="table-fn"}**00.0010.010.050.10.150.20.30.4**D9S26924.29−∞−4.842−1.889−0.0060.620.8610.9360.8280.504D9S27430.24−4.292−3.183−1.85−0.699−0.258−0.0570.0420.0940.055D9S15634.032.8732.872.8442.7072.5012.2631.9961.3880.704D9S92536.753.4583.4523.3973.1482.8242.4852.131.3720.589D9S177841.440.320.3190.3110.2730.2270.1840.1420.0690.017D9S187043.443.6943.6883.6293.3613.0122.6452.2591.4250.554D9S112146.62.1852.1792.1281.8971.5981.2890.9730.37−0.003D9S16949.652.2162.2122.1792.0261.8261.6151.3910.9060.395D9S16151.52.1972.1942.1612.0121.8171.6111.3950.930.444D9S27052.79−∞−0.8590.1040.6340.720.6770.5830.3410.128D9S214953.59−∞−1.745−0.7190.0380.3380.4670.5150.4690.292[^6]

Candidate gene selection and mutation analysis
----------------------------------------------

For the positional cloning we used the NCBI Human genome Build 35 Version 1. At the time of analysis (August 2004), 81 genes (including pseudogenes and predicted genes) were located between the Marker D9S274 and D9S270. Of these 81 genes, 19 were genes or pseudogenes for interferons, which we did not consider as candidate genes, since the clinical and pathological examinations did not suggest an inflammatory aetiology. The locus contained 19 *in silico* predicted genes, and 9 transcripts were pseudogenes. We prioritized the remaining 35 genes using the following criteria: (i) expression in skeletal muscle; (ii) sharing of homology and/or functional domains of the known genes for distal myopathies: *MYH7, GNE, TTN* and *dysferlin*; (iii) structural proteins of skeletal muscle; and (iv) evidence of a functional role in skeletal muscle. A number of possible candidate genes were identified. ADAMTSL1 is expressed in the extracellular matrix, which is essential for muscle integrity, as exemplified by congenital muscular dystrophy resulting from mutations in collagen VI alpha chains. FLJ39267 contains a myosin tail, and coiled coil domain containing two has 24% homology to the myosin heavy chain. Mutations in the myosin heavy chain 7 tail cause Laing type distal myopathy ([@B33]). Endothelial tyrosine kinase contains fibronectin type III domains similar to titin ([@B18]), which if mutated causes distal myopathy type Udd. Finally, *KLHL9* was selected as candidate gene because it contains six kelch domains that function as oligomeric ring canal actin organizers in *Drosophila* ([@B35]). KLHL9 is also expressed in skeletal muscle according to genetic databases such as Genecards (<http://www.genecards.org>).

Sequencing coding exons and intron-exon boundaries of the candidate genes *ADAMTSL1, FLJ39267, TEK* and *CCDC2* did not reveal any mutation. In contrast, a heterozygous missense mutation was detected in *KLHL9*, c.796 T\>C (NM_018847.1), leading to a leucine to phenylalanine substitution at amino-acid position 95, situated in the conserved BTB-domain of the KLHL9 protein. This mutation co-segregated with the disease phenotype as shown in [Supplementary Fig. 2](http://brain.oxfordjournals.org/cgi/content/full/awq108/DC1) and was not observed in 300 healthy unrelated German control individuals.

Alignment of Kelch proteins
---------------------------

KLHL9 is widely distributed across the vertebrates, and genes encoding proteins with \>90% sequence identities with human KLHL9 are present in mammalian, fish and bird genomes ([Fig. 4](#F4){ref-type="fig"}D). All of the putative vertebrate KLHL9 orthologues have a leucine at the equivalent position of Leu-85 in KLHL9. Within the human genome, there are 49 BTB-BACK-Kelch (BBK) proteins and KLHL9 is a typical representative of this group ([@B42]; [@B41]). The residue position equivalent to Leu-95 in KLHL9 is conserved in the human BBK proteins, and is typically a leucine, isoleucine or methionine. The homologous position in other family members ([Fig. 4](#F4){ref-type="fig"}C, red box) also shows a high propensity for large, aliphatic amino acids. Figure 4Structural model of the KLHL9--Cul3 complex and alignment of Kelch proteins. (**A**) The KLHL9 BTB homodimer is shown in light blue/dark blue ribbons and the N-terminal region of Cul3 is shown as two green ribbons. The complex forms a dimer through self-association of the BTB domain, and each BTB domain interacts with the N-terminus of one Cul3 molecule. The two L95 side chains (circled) in the KLHL9 BTB dimer are in the vicinity of two equivalent and independent Cul3-binding interfaces. (**B**) Schematic representation of the BTB-BACK-Kelch and Cul3 proteins in the context of a full-length, functional ubiquitin ligase complex. The red dots indicate the approximate position of KLHL9 residue L95. (**C**) Multiple sequence alignment of the BTB domains from a representative subset of the human BTB-BACK-Kelch proteins, including sequences from Val-65 to Thr-125 in KLHL9. The red asterisk denotes the position of L95 in KLHL9. The homologous position in other family members (red box) shows a high propensity for large, aliphatic amino acids. The blue bars indicate the level of conservation from dark blue (highly conserved) to light blue (less conserved). (**D**) Alignment of several KLHL9 vertebrate proteins. The L95 residue is labelled with a red mark above and shows 100% conservation in vertebrates.

Molecular modelling
-------------------

Modelling studies were used to predict the effects of mutation on KLHL9 function. KLHL9 binds to Cul3 via its BTB-domain in the KLHL9--Cul3--Roc1 E3 ubiquitin ligase complex ([@B15]). The homology-based molecular model of the KLHL9/Cul3 complex places residue L95 of KLHL9 near the intermolecular interface with Cul3 ([Fig. 4](#F4){ref-type="fig"}A). Although L95 does not make direct contact with Cul3 and is mostly buried within the BTB domain, this residue is in close proximity of the Cul3 chain, and replacement of an aliphatic residue with a large aromatic residue at this position would probably affect the conformation of the BTB domain, suggesting that the p.L95F mutation could disrupt the KLHL9/Cul3 complex.

Functional analyses
-------------------

As the p.L95F mutation resides within the BTB domain of KLHL9, we hypothesized that the p.L95F amino-acid substitution reduces association with Cul3. To determine whether the p.L95F mutation within the BTB domain of KLHL9 disrupts association with Cul3, we transfected human embryonic kidney 293T cells with mammalian expression vectors for FLAG epitope-tagged wild-type or p.L95F mutant KLHL9 and increasing amounts of HA-Cul3. The expression levels of HA-Cul3 ([Fig. 5](#F5){ref-type="fig"}A, middle panel) and either wild-type FLAG-KLHL9 ([Fig. 5](#F5){ref-type="fig"}A, lower panel, lanes 1--6) or mutant FLAG-KLHL9-L95F ([Fig. 5](#F5){ref-type="fig"}A, lower panel, lanes 7--11) were confirmed by total α-HA and α-FLAG immunoblots of total lysates, respectively. Our results indicate that while the p.L95F mutation does not alter the total levels of KLHL9, the p.L95F mutation inhibits association with Cul3 (e.g. compare lanes 5--10 and 6--11). Figure 5Functional studies and expression. (**A**) The L95F mutation in KLHL9 reduces association with Cul3. Human embryonic kidney 293T cells were transfected with wild-type cytomegalovirus FLAG-KLHL9 (lanes 1--6) or mutant cytomegalovirus FLAG-L95F KLHL9 (lanes 7--11) and either 0 ng (lanes 1, 2 and 7), 83.3 ng (lanes 3 and 8), 250 ng (lanes 4 and 9), 750 ng (lanes 5 and 10) or 2250 ng of cytomegalovirus HA-Cul3 (lanes 6 and 11) expression vector. Cell lysates were collected at 40 h post-transfection. Equivalent amounts of total protein were immunoprecipitated with α-FLAG antibody and subjected to an α-HA immunoblot (upper panel). Total α-HA (middle panel) and α-FLAG (lower panel) blots were conducted in parallel to confirm the expression of the respective proteins. Our results clearly demonstrate that the p.L95F mutation reduces association with Cul3 (compare lanes 5 to 10 and 6 to 11, for example). (**B**) KLHL9 is expressed in multiple tissues. To examine the tissue distribution of KLHL9, a human cDNA panel was screened by RT-PCR. PCR products were analysed on a 2% agarose gel. The results were confirmed to be within the linear range by limited dilution of the cDNA products. Quantification of KLHL9 expression is shown in [Supplementary Table 1](http://brain.oxfordjournals.org/cgi/content/full/awq108/DC1).

Expression profiling
--------------------

To examine the tissue distribution of KLHL9, we performed RT-PCR on a human tissue cDNA panel. KLHL9 was expressed in skeletal muscle and multiple tissues at moderate to high levels with the exception of liver, colon, small intestine, the thyroid gland, pancreas and uterus, where KLHL9 was expressed at low levels ([Fig. 5](#F5){ref-type="fig"}B, [Supplementary Table 1](http://brain.oxfordjournals.org/cgi/content/full/awq108/DC1)).

Discussion
==========

In this report, we describe a family with a childhood onset distal myopathy with autosomal dominant inheritance. The phenotype bears similarities to the distal myopathy with childhood onset previously described by Laing and Voit ([@B28]; [@B48]; [@B32]; [@B33]; [@B29]). Patients with Laing myopathy also have onset of muscle weakness in the anterior lower leg, followed by slowly progressive weakness and involvement of proximal muscles. In both disorders, weakness of finger extensors and hip extensors followed many years later. In contrast to the Laing myopathy phenotype, however, affected members of the family described here did not demonstrate neck flexor weakness or shoulder girdle weakness. The early onset and the slow progression as well as the distribution of affected muscles were also clearly different from the myopathies described by Welander, Markesbery--Griggs, Udd, Nonaka and Miyoshi. Furthermore, the respective loci for these and other relevant conditions were excluded by exclusion mapping. The histopathological investigation of sural nerve was normal at the age of 16 years for the index case, and electrophysiological studies showed only minor abnormalities. Clinical features including areflexia and sensory disturbances in stocking-glove distribution in several family members were distinctive.

A total genome scan identified the disease locus at 9p21.2-p22.3. A number of possible candidate genes were identified in this interval but only the sequencing of the *KLHL9* revealed a mutation c.796 T\>C (NM_018847.1) leading to a p.L95F amino-acid substitution in the conserved N-terminal BTB-domain, which we consider to be pathogenic.

KLHL9 binds to Cul3 via its BTB domain to form an E3 ubiquitin ligase complex ([@B15]). Interestingly, Cul3 is expressed in highest levels in skeletal muscle tissue ([@B13]), pointing to a myopathological effect of this mutation. The p.L95F mutation is located in the conserved N-terminal BTB-domain of KLHL9, and it is known that the deletion of the BTB-domain of KLHL9 abolishes Cul3 binding ([@B15]). L95 is located near the intermolecular interface with Cul3 ([Fig. 4](#F4){ref-type="fig"}A). A mutation at this position is likely to affect the conformation of this region of the BTB domain. Indeed, pull-down assays revealed that the p.L95F mutation diminishes association with Cul3 *in vitro* ([Fig. 5](#F5){ref-type="fig"}A). As mentioned above, KLHL9 forms a part of the KLHL9--Cul3--Roc1 E3 ubiquitin ligase complex and functions as a substrate adaptor that targets substrate proteins via its six Kelch domains for ubiquitination by the KLHL9--Cul3--Roc1 E3 ubiquitin ligase ([@B15]). Hence, the targeted substrates of KLHL9 for ubiquitination and later degradation by the proteasome might accumulate, serving as a possible pathophysiological mechanism of the distal myopathy in our patients. It has recently been published that KLHL9 targets the Aurora B kinase on mitotic chromosomes and regulates mitotic progression and completion of cytokinesis in human cells ([@B43]). Aurora B regulates the assembly and disassembly of type III intermediate filaments including vimentin, desmin and peripherin as well as the axonally expressed type IV neurofilaments ([@B39]). The clinical pattern of distal myopathy and sensory disturbances could be explained by the hypothetical interference of the *KLHL9* mutation with the Aurora B kinase function, which is targeted for degradation by KLHL9 ([@B43]).

Our hypothesis of Aurora B kinase missregulation certainly needs to be tested in further experiments. The homologue of *KLHL9* in the zebrafish *klhl* and its human orthologue *KLHL* display conserved expression patterns in skeletal and cardiac muscles ([@B50]). We did not find clinical evidence of cardiac involvement in this family. The facts and the course of the disease in this family suggest that *KLHL9* mutations primarily affect muscle function, but it may be, to a lesser extent, important for the conservation of nerve function.

One possible pathophysiological mechanism may be the interaction between KLHL9 and Smad3 ([@B17]), which is a myogenic transcription factor ([@B30]). The exact role of KLHL9 in muscle and nerve homeostasis remains to be determined.

The KLHL9 protein belongs to the BTB-Kelch family of proteins that includes gigaxonin, a protein which is mutated in giant-axonal neuropathy (MIM 256550) ([@B7]). Gigaxonin controls the degradation of microtubule-associated protein 8 (MAP1B) and tubulin-binding cofactor B, and leads to a neurodegenerative disorder of peripheral neuropathy due to impaired retrograde axonal transport and neuronal death ([@B12]). The *gigaxonin* gene is as ubiquitously expressed as the *KLHL9* gene ([Fig. 5](#F5){ref-type="fig"}B), and it causes a peculiar neurodegenerative disorder affecting the peripheral nerve and CNS. A mutation in *KLHL9* leads to distal myopathy with associated sensory disturbances in several affected patients. Interestingly, several E3 ubiquitin ligases such as atrogin-1 and MuRF1 are markedly up-regulated in muscle atrophy ([@B24]). Trim32, another ubiquitin ligase, is mutated in limb girdle muscular dystrophy 2H (MIM 254110) ([@B27]). Identification of targeted proteins of the KLHL9--Cul3--Roc1 complex may provide further understanding of the molecular pathogenesis of KLHL9-related distal myopathies and also unravel new candidate genes for distal myopathies. We did not find additional cases of *KLHL9* mutations in a cohort of 20 cases representing a broad spectrum of clinical presentations of distal myopathy (data not shown). Further families and cases need to be identified to understand the clinical spectrum of *KLHL9* myopathy and the neurogenic component of this disease.

In conclusion, we report on a novel form of early onset autosomal dominant distal myopathy. This novel disorder is caused by the heterozygous missense mutation p.L95F of KLHL9*.* KLHL9 is a substrate adaptor of the Cul3--E3--ubiquitin ligase. The p.L95F mutation is located in the conserved BTB domain of KLHL9, which mediates interaction with Cul3, while the Kelch repeats mediate association with substrates. We were able to demonstrate that the mutation p.L95F diminishes the binding of KLHL9 to Cul3. The KLHL9--Cul3--E3 ubiquitin ligase represents a novel pathway leading to an early onset distal myopathy in contrast to the proteins encoded by other mutated genes in distal myopathies: UDP-N-acetylglucosamine 2-epimerase is an enzyme ([@B14]); dysferlin is a membrane protein ([@B31]); titin ([@B18]), nebulin ([@B49]) and myosin heavy chain-7 ([@B33]) are all sarcomeric proteins ([@B45]). We propose that the distal myopathy observed in this German family should be included in the classification schemes of distal myopathies as an early childhood onset distal myopathy, associated with mutations in the *KLHL9* gene.
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BTB 

:    bric-a-brac

Cul3 

:    Cullin 3

HA-Cul3

:   Human influenza hemagglutinin (HA) Tag-cullin3

*KLHL9* 

:    kelch-like homologue 9 gene

RT-PCR 

:    reverse transcriptase polymerase chain reaction

[^1]: Patient ID according to pedigree in [Fig. 1](#F1){ref-type="fig"}.

[^2]: L = left; R = right; Amplitude = amplitude of compound muscle action potential; n.a.= not available; n.o =not obtained. Normal values are presented as mean ± SD (range). All the reference values and the range are in italics.

[^3]: a Normal values from [@B8].

[^4]: b ≥2 SD from control (increase for distal latencies).

[^5]: c Normal values from [@B6].

[^6]: a Marker position in cM refers to the DeCODE Map.
